Insigneo Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$293K Sell
656
-629
-49% -$293K 0.02% 511
2025
Q4
$583K Sell
1,285
-7
-0.5% -$3.02K 0.04% 326
2025
Q3
$506K Sell
1,292
-33
-2% -$13.8K 0.04% 359
2025
Q2
$590K Buy
1,325
+238
+22% +$110K 0.05% 299
2025
Q1
$527K Sell
1,087
-173
-14% -$80.6K 0.05% 290
2024
Q4
$507K Sell
1,260
-54
-4% -$25K 0.05% 294
2024
Q3
$611K Buy
1,314
+65
+5% +$31.2K 0.06% 274
2024
Q2
$596K Buy
1,249
+646
+107% +$280K 0.07% 255
2024
Q1
$252K Buy
603
+63
+12% +$26.6K 0.03% 424
2023
Q4
$220K Buy
+540
New +$199K 0.03% 403
2023
Q3
Sell
-1,084
Closed -$381K 400
2023
Q2
$381K Buy
+1,084
New +$365K 0.07% 243

Other funds holding VRTX

Insigneo Advisory Services's VRTX Position: Q1 2026 in Review

Insigneo Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 49% in Q1 2026, selling an estimated $293K and leaving 656 shares worth $293K. The position accounts for 0.02% of the portfolio, ranked #511.

Insigneo Advisory Services first reported a position in VRTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $611K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Insigneo Advisory Services held 656 shares of Vertex Pharmaceuticals worth $293K as of Q1 2026.
  • Insigneo Advisory Services sold 629 Vertex Pharmaceuticals shares in Q1 2026, an estimated $293K.
  • Vertex Pharmaceuticals made up 0.02% of Insigneo Advisory Services's portfolio in Q1 2026, its #511 holding.
  • Insigneo Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Insigneo Advisory Services's Vertex Pharmaceuticals position peaked at $611K in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Insigneo Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.